

BIOMARKER EXPRESSION IN AN ADHESIVE PATCH-BASED ASSAY FOR PIGMENTED LESIONS

Lynh Nguyen, Elanee Simmons, Alexandra Vaughn, John D. McPherson, Maija Kiuru University of California Davis, Departments of Dermatology, Pathology and Laboratory Medicine, and Biochemistry and Molecular Medicine, Sacramento, CA

INTRODUCTION

- Early diagnosis of melanoma is critical for improved survival as melanoma is the deadliest of the common forms of skin cancer.
- The gold standard for the diagnosis of melanoma is a biopsy followed by histopathological analysis.
- Melanocytic nevi, which are very common benign neoplasms of the melanocytes, are often biopsied because they are mimics and precursor for melanoma¹. Annually, 4.5 million pigmented lesions are biopsied in the United States².
- A subset of melanoma is difficult to distinguish from melanocytic nevi, resulting in diagnostic errors and worsened patient outcomes.
- Therefore, improved diagnostic tests, including the utilization of novel biomarkers, are being developed to improve clinical and histological diagnostic accuracy of melanoma.
- Moreover, non-invasive tests prior to surgical biopsy have been introduced, including an adhesive patch-based assay that tests the expression of melanoma biomarkers PRAME and noncoding long RNA LINC005183.
- Our prior work identified that S100A8, a member of the calcium-binding S100 family, is differentially expressed in melanomas versus nevi⁴. Specifically, S100A8 is expressed by the keratinocyte microenvironment of melanomas but not nevi⁵.
- S100A8 is a melanoma biomarker of interest for an adhesive patch-based assay, because it is expressed in the epidermis, the most superficial layer of the skin⁵.

• S100A8 expression is upregulated in melanoma, and it will be detectable by an adhesive patch test.


METHOD

STUDY DESIGN & SETTING:

S100A8: DETECTED

This is a prospective observational study, whose subjects are recruited from the UC Davis Dermatology Clinic.

OVERVIEW OF STUDY:



DISCUSSION

S100A8 primer used

Hybridization and amplification

- This project aims to investigate gene expression of \$100A8, a novel melanoma biomarker of the epidermal keratinocyte microenvironment, in pigmented lesions utilizing a non-invasive, adhesive patch-based assay.
- The utility of adhesive patch-based assays for pigmented lesion assessment has been previously demonstrated with an assay that tests the expression of melanoma biomarkers *PRAME* and noncoding long RNA LINC00518.
- As S100A8 is expressed in the keratinocytes of the epidermis, the most superficial layer of the skin, it may offer additional benefits for adhesive patch-based testing that is based on collection of RNA from the top layer of the epidermis.
- The use of \$100A8 adhesive patch-based gene expression testing may facilitate a more accurate diagnosis of melanocytic lesions, in addition to clinical and histopathological assessment.

REFERENCES

- 1. Elder DE. Precursors to melanoma and their mimics: Nevi of special sites. Modern Pathology. 2006 Feb;19 Suppl 2:S4-20.
- 2. Brouha B, Ferris L, Skelsey MK, et al. Genomic atypia to enrich melanoma positivity in biopsied lesions: Gene expression and pathology findings from a large U.S. Registry study. The National Society for Cutaneous Medicine. 2021 Jan;5(1):13-18.
- 3. Gerami P, Yao Z, Polsky D, et al. Development and validation of a noninvasive 2-gene molecular assay for cutaneous melanoma. Journal of the American Academy of Dermatology. 2017 Jan;76(1):114–120.
- 4. Gebhardt C, Németh J, Angel P, Hess J. S100A8 and S100A9 in inflammation and cancer. Biochemical Pharmacology. 2006 Nov;72(11):1622-1631.
- 5. Kiuru M & Kriner MA, Wong S, Zhu G, et al. High-plex spatial RNA profiling reveals cell type-specific biomarker expression during melanoma. Submitted.

ACKNOWLEDGMENTS

Dr. Kiuru's involvement in this study is supported, in part, by the National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health through grant #K23AR074530.



OBJECTIVE